Key Highlights
•
Inhibition of the protein HMGB1 was found to restore adult hippocampal neurogenesis and spatial learning in a mouse model after adolescent binge alcohol exposure. This finding suggests a potential therapeutic target for reversing cognitive deficits associated with alcohol use disorder.
Source →
•
Learning about financial compensation for participation in Alzheimer’s disease research was found to potentially reduce enrollment rates, especially among highly educated individuals. This suggests that disclosing monetary incentives may conflict with participants’ altruistic motivations, a key factor for designing effective recruitment strategies for neurological studies.
Source →
•
A new MRI contrast agent was used to estimate physiological parameters affecting amyloid plaque distribution in the brains of Alzheimer’s disease transgenic mice. This advancement could improve the detection and understanding of amyloid plaque formation, a core feature of Alzheimer’s pathology.
Source →
•
UK guidelines for the appropriate use of the amyloid-targeting antibody lecanemab in Alzheimer’s disease were published, highlighting the drug’s ability to remove amyloid beta plaques from the brain. This marks a significant milestone in moving towards disease-modifying therapies for Alzheimer’s, though challenges with implementation and reimbursement remain.
Source →
Stay curious. Stay informed —
Science Briefing
